CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that two abstracts related to its investigational oral JAK3 inhibitor, VX-509, will be presented at the 2011 Annual Meeting for the American College of Rheumatology (ACR) in Chicago, November 5-9, 2011. Presentations will include final data from a recently completed Phase 2 study of VX-509 in rheumatoid arthritis (RA) as well as preclinical data in models of inflammation that supported the Phase 2 study and provide a rationale for further evaluation of VX-509 in a number of immune-mediated inflammatory diseases. Vertex announced top-line results from the Phase 2 study in September, and final data will be presented at ACR.
